Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease

Neuroscience Letters

Volumn 614, Issue , 2016, Pages 7-15

  Zhang, Ji ^a,b   Yang, Beibei ^a   Sun, Hongbin ^a   Zhou, Yan ^a   Liu, Mengdi ^a   Ding, Jianhua ^a   Fang, Feng ^a   Fan, Yi ^a   Hu, Gang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aquaporin 4; Astrocyte; Dopamine; Neurodegeneration; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AQUAPORIN 4; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL; ASTROCYTE; CHRONIC DISEASE; DOPAMINERGIC NERVE CELL; GENETICS; GLIA; KNOCKOUT MOUSE; METABOLISM; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACUTE DISEASE; ANIMALS; AQUAPORIN 4; ASTROCYTES; CHRONIC DISEASE; DOPAMINERGIC NEURONS; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN-1BETA; MICE, KNOCKOUT; NERVE DEGENERATION; NEUROGLIA; PARKINSON DISEASE; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; VENTRAL TEGMENTAL AREA;

EID: 84952888717     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.12.057     Document Type: Article

References (42)

1. Allain H., Bentue-Ferrer D., Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog. Neurobiol. 2008, 84:25-39.
2. Baydyuk M., Nguyen M.T., Xu B. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp. Neurol. 2011, 228:118-125.
3. Borgal L., Hong M., Sadi D., Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience 2007, 147:712-719.
4. Chi Y., Fan Y., He L., Liu W., Wen X., Zhou S., Wang X., Zhang C., Kong H., Sonoda L., Tripathi P., Li C.J., Yu M.S., Su C., Hu G. Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. Aging cell 2011, 10:368-382.
5. Colangelo A.M., Alberghina L., Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci. Lett. 2014, 565:59-64.
6. Cox F.F., Berezin V., Bock E., Lynch M.A. The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner. Neuroscience 2013, 235:141-148.
7. Dawson T., Mandir A., Lee M. Animal models of PD: pieces of the same puzzle?. Neuron 2002, 35:219-222.
8. Double K.L., Reyes S., Werry E.L., Halliday G.M. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?. Prog. Neurobiol. 2010, 92:316-329.
9. Douhou A., Debeir T., Michel P.P., Stankovski L., Oueghlani-Bouslama L., Verney C., Raisman-Vozari R. Differential activation of astrocytes and microglia during post-natal development of dopaminergic neuronal death in the weaver mouse. Brain Res. Dev. Brain Res. 2003, 145:9-17.
10. Fan Y., Kong H., Shi X., Sun X., Ding J., Wu J., Hu G. Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation. Neurobiol. Aging 2008, 29:1226-1236.
11. Fan Y., Zhang J., Sun X.L., Gao L., Zeng X.N., Ding J.H., Cao C., Niu L., Hu G. Sex- and region-specific alterations of basal amino acid and monoamine metabolism in the brain of aquaporin-4 knockout mice. J. Neurosci. Res. 2005, 82:458-464.
12. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
13. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 2010, 184:133-157.
14. Greene J.G., Dingledine R., Greenamyre J.T. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol. Dis. 2005, 18:19-31.
15. Halassa M.M., Haydon P.G. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 2010, 72:335-355.
16. Hammond C., Bergman H., Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 2007, 30:357-364.
17. Hegarty S.V., Sullivan A.M., O'Keeffe G.W. Roles for the TGFbeta superfamily in the development and survival of midbrain dopaminergic neurons. Mol. Neurobiol. 2014, 50:559-573.
18. Herrera A.J., Tomas-Camardiel M., Venero J.L., Cano J., Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural Transm. 2005, 112:111-119.
19. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
20. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
21. Kalia L.V., Lang A.E. Parkinson's disease. Lancet 2015.
22. Kholodilov N., Yarygina O., Oo T.F., Zhang H., Sulzer D., Dauer W., Burke R.E. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. J. Neurosci. 2004, 24:3136-3146.
23. Kimelberg H.K. Functions of mature mammalian astrocytes: a current view. Neuroscientist 2010, 16:79-106.
24. Kuppers E., Gleiser C., Brito V., Wachter B., Pauly T., Hirt B., Grissmer S. AQP4 expression in striatal primary cultures is regulated by dopamine-implications for proliferation of astrocytes. Eur. J. Neurosci. 2008, 28:2173-2182.
25. Liss B., Haeckel O., Wildmann J., Miki T., Seino S., Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 2005, 8:1742-1751.
26. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
27. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., Dagher A., Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510.
28. Meredith G.E., Totterdell S., Potashkin J.A., Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S112-S115.
29. Nagelhus E.A., Ottersen O.P. Physiological roles of aquaporin-4 in brain. Physiol. Rev. 2013, 93:1543-1562.
30. Nicchia G.P., Srinivas M., Li W., Brosnan C.F., Frigeri A., Spray D.C. New possible roles for aquaporin-4 in astrocytes: cell cytoskeleton and functional relationship with connexin43. FASEB J. 2005, 19:1674-1676.
31. Otto D., Unsicker K. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Glia 1994, 11:47-56.
32. Pekny M., Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol. Rev. 2014, 94:1077-1098.
33. Rinne J.O. Nigral degeneration in Parkinson's disease. Mov. Disord. 1993, 8(Suppl. 1):S31-S35.
34. Rocha S.M., Cristovao A.C., Campos F.L., Fonseca C.P., Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol. Dis. 2012, 47:407-415.
35. Smith M.P., Cass W.A. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci. Lett. 2007, 412:259-263.
36. Tarazi F.I., Sahli Z.T., Wolny M., Mousa S.A. Emerging therapies for Parkinson's disease: from bench to bedside. Pharmacol. Ther. 2014.
37. Thenral S.T., Vanisree A.J. Peripheral assessment of the genes AQP4, PBP and TH in patients with Parkinson's disease. Neurochem. Res. 2012, 37:512-515.
38. Thompson L., Barraud P., Andersson E., Kirik D., Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 2005, 25:6467-6477.
39. Tomas-Camardiel M., Venero J.L., de Pablos R.M., Rite I., Machado A., Cano J. In vivo expression of aquaporin-4 by reactive microglia. J. Neurochem. 2004, 91:891-899.
40. Yang Y.X., Wood N.W., Latchman D.S. Molecular basis of Parkinson's disease. Neuroreport 2009, 20:150-156.
41. Zeng X.N., Sun X.L., Gao L., Fan Y., Ding J.H., Hu G. Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol. Cell. Neurosci. 2007, 34:34-39.
42. Zhou J., Kong H., Hua X., Xiao M., Ding J., Hu G. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport 2008, 19:1-5.